Wednesday, 25 Apr 2018

You are here

The Consequences and Cure of Hepatitis C

I spent this past week seeing hepatitis C patients with our hepatologists, and being a rheumatologist, I was looking forward to seeing extra-hepatic manifestations of HCV that we read about in text-books - cryoglobulinemic vasculitis, sicca syndrome, porphyria cutanea tarda and many others. I suppose I should not be surprised that the week passed without seeing a single one of these. 

While a wide array of extra-hepatic manifestations, including may rheumatic rheumatologic, will occur in 40-70% of chronic HCV patients, the advent of direct acting antivirals (DAA) has changed HCV outcomes, such that I do not think we will be seeing these cases much longer. 

In the early days of HCV treatment with interferon therapy one could hope to achieve sustained virological response (SVR in 6% of patients, and with significant side effects. Now DAAs boast > 96% cure rates in 8-12 weeks, depending on the drug and presence or absence of cirrhosis. Some of the drugs are even pan-genotypic. 

What can we still do as rheumatologists? We can screen our rheumatology patients for hepatitis C. 

Yesterday I saw a new hepatitis C patient: 71 year old male with a history IV drug abuse in the 1970s and had 20 tattoos, who no one ever thought to screen for hepatitis C until he saw his new primary care doctor last week. In fact, the patient had never heard of hepatitis C before. 

The CDC currently recommends screening for hepatitis C in any adult born between 1945 and 1965, or if any history of IV drug use, hemodialysis, HIV, received products or organs before 1992 or have persistently elevated ALT levels. https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm 

In our rheumatology department, we screen all patients for hepatitis B prior to starting immunosuppression, and our hepatitis remote panel conveniently includes a hepatitis C antibody. If a patient is found to be positive, HCV viral load should be sent and if elevated referred to hepatology.

While there are currently many barriers to administering DAAs to cure hepatitis C (most centered around cost and insurance companies), the World Health Organization’s strategy to eliminate hepatitis C infection by 2020 seems overly ambitious, I do think we are well on our way. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

One point not mentioned in the article is a false positive RF due to hepatitis C. I pick up two or three hepatitis C cases a year when a patient is referred to me with suspected RA because of arthralgias and a weakly positive RF.

More Like This

Lupus Subgroup Responds to Anti-CD22

The monoclonal antibody epratuzumab showed promise as a B-cell depleting agent in patients with concomitant systemic lupus erythematosus (SLE) and Sjogren's syndrome, a post-hoc analysis of two phase III trials found.

Wear Your Pajamas to Work for Lupus

I suspect that everyone in rheumatology has a special place in their hearts for lupus patients. Their disease is so cruel, and we have so little to offer them, but the young women (and some men) that I treat keep battling on. The longer I have cared for them, the more I wanted to do for them. Managing their illness alone did not seem like enough. 

SynBioSe: Combo Rituximab and Belimumab Succeeds in Severe Refractory Lupus

One of the driving pathogenic mechanisms in systemic lupus erythematosus (SLE) is the generation of immune complexes capable of inducing netosis (NET formation) and NET-derived DNA that may be an amplifying autoantigen and give rise to anti-nuclear autoantibodies (ANAs). 

Increased Comorbidity Burden in Lupus African Americans

Researchers from Vanderbilt University Medical Center used electronic health records (EHR) to perform a phenome-wide study comparing African American (AA-SLE) and Caucasian (C-SLE) with systemic lupus erythematosus (SLE) and found more comorbidities in AA-SLE, especially renal, cardiovascular, and infectious diseases.

mTOR Inhibition with Sirolimus Effective in Lupus

Lancet reports that 12 months of sirolimus treatment is associated with improvement in lupus disease activity presumeably by correction of pro-inflammatory T-cell activity.